Ataxia-Telangiectasia (AT) Study - Wesley Research Institute
Wesley Research Institute

Ataxia-Telangiectasia (A-T) is a rare genetic disorder with an incidence of approximately three in one million births. Patients with A-T often end up in a wheelchair by the age of ten and have a life expectancy of 25 years. Approximately 40 people in Australia currently have A-T.


Research Objectives





Study location

Wesley Research Institute

Study type

Investigator Initiated

Patient group

Patients with Ataxia-Telangiectasia (AT)

About this clinical trial

This genetic disorder leads to ataxia; the inability to walk, talk and use fine motor skills because of the neurological impairment. A-T patients also suffer from cystic-fibrosis-like lung disease due to immunodeficiency as well as cancer accounting for a high death rate.

The symptoms of A-T are described as the ‘worst parts’ of cerebral palsy, cystic fibrosis and muscular dystrophy with a high risk of cancer and lung disease. There is unfortunately no effective therapy for this illness.

This study will investigate the use of Triheptanoin, a dietary fat supplement which has the potential to boost energy metabolism and significantly improve neurological symptoms. This trial has given families of patients the hope that they are able to have their children for longer by slowing down the progression of the disease.

Lead investigator

  • Prof David Coman

Clinical trial coordinator

  • Sarah Harriman

This clinical trial is now closed for recruitment

If you would like more information about this trial, please complete the contact form below.

I consent to receive updates on Wesley Research Institute news and events, clinical trials, research projects and how to support WRI.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram